New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
04:55 EDTESALY, ESALY, PRXL, PRXL, WAG, WAG, COV, COV, PFE, PFE, SNY, SNY, AMGN, AMGN, CPB, CPB, JNJ, JNJ, MYL, MYL, LO, LOFood & Drug Law Institute to hold a conference
2014 FDLI Annual Conference is being held in Washington, D.C. on April 23-24.
News For ESALY;MYL;JNJ;CPB;AMGN;SNY;PFE;COV;WAG;PRXL;LO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 18, 2015
07:32 EDTMYLMylan sued in connection with filing of ANDA for Abiraterone Acetate Tablets
Subscribe for More Information
August 17, 2015
11:13 EDTPRXLPAREXEL calls active on wide price movement
Subscribe for More Information
11:01 EDTPRXLPAREXEL jumps 9% to $74.44 in morning trading
Subscribe for More Information
08:23 EDTAMGNDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
August 14, 2015
17:08 EDTMYLPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:44 EDTAMGNThird Point gives quarterly update on stakes
NEW STAKES: Baxter (BAX), T-Mobile (TMUS), Sealed Air (SEE), Devon (DVN), and Perrigo (PRGO). INCREASED STAKES: SunEdison (SUNE), Dow Chemical (DOW), Mohawk (MHK), Yum! Brands (YUM), and IAC/InterActiveCorp (IACI). DECREASED STAKES: Ally Financial (ALLY), Amgen (AMGN), Sensata (ST), Masco (MAS), and Delta (DAL). LIQUIDATED STAKES: Dollar General (DG), McKesson (MCK), Edgewell Personal Care (EPC), Maxim (MXIM), and FleetCor (FLT).
16:37 EDTMYLAppaloosa gives quarterly update on stakes, takes stake in Apple
Subscribe for More Information
13:33 EDTMYLPaulson & Co. votes in support of Mylan's proposed merger with Perrigo
Subscribe for More Information
12:12 EDTMYLPaulson recently took position in Perrigo, WSJ reports
John Paulson's hedge fund, which owns a 4.6% stake in Mylan (MYL), recently built a position in Perrigo (PRGO), Wall Street Journal reports, citing people familiar with the matter. Mylan has made an unsolicited bid to acquire Perrigo. Shares of Perrigo moved up following the report, and sit up 85c to $193.35 in midday trading.
11:10 EDTMYLPerrigo says ISS affirms position that Mylan deal would be 'value destructive'
Subscribe for More Information
09:20 EDTMYLMylan responds to ISS recommendation regarding Perrigo transaction
Subscribe for More Information
08:59 EDTMYLMylan tells holders board unanimously recommends Perrigo deal
Subscribe for More Information
08:36 EDTPFEPfizer's pending Hospira acquisition approved by Canadian Competition Bureau
Pfizer (PFE) announced that it received approval from the Canadian Competition Bureau with respect to its pending acquisition of Hospira (HSP). As part of its agreement with the Canadian Competition Bureau, Pfizer has committed to divest certain assets in Canada. "We are pleased the Canadian Competition Bureau concluded its review of the transaction and approved the pending combination of Pfizer and Hospira," said Ian Read, chairman and CEO of Pfizer. "We continue to work cooperatively with the regulatory agencies to obtain the requisite approvals, and continue to expect the transaction to close in the second half of 2015."
08:35 EDTMYL, PFEHayman takes Mylan, Perrigo stakes, boasts exposure to energy
Subscribe for More Information
08:26 EDTPFEPiper says Street $4B too low on Pfizer 2019 sales estimates
Piper Jaffray analyst Richard Purkiss believes the Street is underestimating Pfizer's 2019 sales by $4B. The consensus 2019 revenue estimate is $58.7B. Analysts are factoring in "overly conservative" growth assumptions for five of Pfizer's key brands, namely Prevnar, Ibrance, Xeljanz, Eliquis and Lyrica, Purkiss tells investors in a research note. Sentiment towards the stock will "improve meaningfully" as investors "wake up" to the sales turnaround from 2015, the analyst believes. Purkiss expects Pfizer's 36% discount to his $48 target price to close as sentiment improves and reiterates an Overweight rating on the pharma giant. The stock end yesterday's trading down 1c to $35.36.
08:23 EDTMYLMylan still in 'decent' position to win Perrigo vote, CNBC's Faber reports
Subscribe for More Information
08:22 EDTMYLISS tells Mylan investors to vote against Perrigo takeover, WSJ reports
Proxy adviser Institutional Shareholder Services, or ISS, recommended that Mylan (MYL) investors vote against approving the company's $36B takeover of Perrigo (PRGO), the Wall Street Journal reports. ISS said that the deal faces too many hurdles and has "unreasonable uncertainties" associated with it, the report says. Reference Link
August 13, 2015
13:43 EDTMYLPerrigo comments on Mylan's 'reckless' lowering of tender threshold
Perrigo Company (PRGO) responded to the announcement that Mylan N.V. (MYL) has lowered the acceptance condition for its proposed unsolicited offer to acquire Perrigo from not less than 80% of Perrigo ordinary shares to greater than 50% of Perrigo ordinary shares. Perrigo Chairman, President and CEO Joseph C. Papa said, "Mylan already proposed a dilutive deal that substantially undervalues Perrigo; today's announcement makes it even worse. This scare tactic is simply an attempt to coerce Perrigo shareholders into a value destructive deal. We don't believe Perrigo shareholders will tender into this transaction at any threshold and we are confident that there is no rational path to a full acquisition of Perrigo. This move is an obvious sign of desperation that would have profoundly negative effects for shareholders, debtholders, customers and employees of both Perrigo and Mylan. Under Irish law, this structure all but guarantees that the promised synergy realization will fail and it would create material credit and equity risk for both companies - none of which Mylan has detailed to its own shareholders or ours." Papa continued, "This reckless action runs contrary to the best interests of both Perrigo and Mylan shareholders, taking a value destructive transaction and making it materially worse when Mylan fails to achieve the 80% threshold necessary for consolidation. This is yet another example of Mylan's leadership disregarding their fiduciary responsibilities to represent the best interests of shareholders."
08:16 EDTPFEPfizer receives approval from ACCC for pending acquisition of Hospira
Pfizer (PFE) announced that the Australian Competition and Consumer Commission has approved the company's pending acquisition of Hospira (HSP) and found no need for remedies. Completion of the transaction remains subject to the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, governmental and regulatory approvals in certain other jurisdictions and other usual and customary closing conditions. Pfizer continus to expect the transaction to close in the second half of 2015.
07:02 EDTMYLMylan lowers acceptance condition on Perrigo offer to greater than 50%
Mylan (MYL) announced that it has formally lowered the acceptance condition for its offer to acquire Perrigo (PRGO) from not less than 80% of Perrigo ordinary shares to greater than 50% of Perrigo ordinary shares. As previously announced, on Aug. 6, 2015, Mylan entered Amendment No. 2 to its bridge credit agreement which allows Mylan to lower the acceptance condition to a number of Perrigo ordinary shares representing more than 50% of the voting rights then exercisable at a general meeting of Perrigo without further consent from the lenders. On April 24, 2015, Mylan issued a Rule 2.5 announcement under the Irish Takeover Rules setting forth its legally-binding commitment to commence an offer directly to the Perrigo shareholders for the entire issued and to be issued share capital of Perrigo. The proposed transaction remains subject to the pre-condition and certain conditions and other terms set forth in the formal Rule 2.5 announcement.
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use